Table 1.
Baseline Characteristics in the 1:1 Potency Ratio and 1:2 Potency Ratio Comparison Groups
| Characteristic | Chlorthalidone 25 mg | Hydrochlorothiazide 25 mg | Hydrochlorothiazide 50 mg |
|---|---|---|---|
| Total cohort, No. | 214 | 428 | 214 |
| Mean age, y | 58.8 | 59.1 | 58.6 |
| Female sex, % | 53.3 | 54.7 | 53.7 |
| Male sex, % | 46.7 | 45.3 | 46.3 |
| Race, % | |||
| White | 84.6 | 81.5 | 74.8 |
| Black | 10.7 | 8.4a | 16.4 |
| Other | 4.7 | 10 | 8.9b |
| Insurance coverage, % | |||
| Commercial | 72.0 | 70.1 | 72.9 |
| Medicare | 25.7 | 26.2 | 24.2 |
| Both | 2.3 | 3.7 | 2.8 |
| Hypertension monotherapy, % | 6.5 | 59.8a | 29.9b |
| Hypertension combination pharmacotherapy, % | 93.5 | 40.2a | 70.1b |
| Other antihypertensive agents used, No. (%)c | |||
| ACE inhibitor | 25 (33.3) | 50 (31.3) | 17 (20.7) |
| ARB | 5 (6.7) | 8 (5.0) | 2 (2.4) |
| β‐Blocker | 34 (45.3) | 58 (36.3) | 31 (37.8) |
| CCB | 8 (10.7) | 32 (20.0) | 25 (30.5) |
| Other | 3 (4.0) | 12 (7.5) | 7 (8.5) |
| Mean chronic conditions indicator | 2.09 | 2.05 | 2.12 |
| Diabetes mellitus, % | 14.5 | 14.0 | 13.1 |
| Chronic kidney disease, % | 0.9 | 0.9 | 0 |
| Mean glomerular filtration rate, mL/min/1.73 m2 d | 75.1 (n=140) | 75.9 (n=304) | 72.8 (n=154) |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
a
P<.05 for chlorthalidone 25 mg vs hydrochlorothiazide 25 mg.
b
P<.05 for chlorthalidone 25 mg vs hydrochlorothiazide 50 mg.
c
Only a subset of the total number of patients in each of the study groups took other hypertensive agents.
d
Complete data needed to calculate this parameter were available for only a portion of the study population